The distribution of preservation times is shown in Fig
The Semaglutide + BPC-157 Consent Form is designed to obtain patient consent for treatments involving Semaglutide and BPC-157, both aimed at chronic weight management
Common explanations include: Alcohol exposure , especially if intake has crept up during work travel, client dinners, or periods of poor recovery Medication effects , including prescription drugs that affect liver enzyme activity Supplement burden , particularly when someone is using multiple performance, fat-loss, or bodybuilding products without clear oversight Metabolic dysfunction , such as fatty liver or insulin resistance Bile duct or cholestatic problems , which become more concerning if ALP, bilirubin, itch, pale stools, dark urine, or abdominal pain are part of the picture That spread is why I do not read a raised GGT as a standalone verdict
in high concentrations it provokes liver damage during cholestasis and promotes colon carcinogenesis in experimental animals[54,55]